Lv6
1938 积分 2025-03-04 加入
Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database
1个月前
已完结
Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape
2个月前
已完结
Structural and Physicochemical Features of Oral PROTACs
2个月前
已完结
Correction to "Closing the Design-Make-Test-Analyze Loop: Interplay between Experiments and Predictions Drives PROTACs Bioavailability"
3个月前
已完结
Property-Based Prediction Uncovers Intestinal Excretion as an Elimination Route of Small-Molecule Drugs
3个月前
已完结
Quantitative Cytochrome P450 3A4 Induction Risk Assessment Using Human Hepatocytes Complemented with Pregnane X Receptor-Activating Profiles
3个月前
已完结
Calculating safety margins using total plasma concentration versus unbound plasma concentration - does it make a difference?
3个月前
已关闭
Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability
4个月前
已完结
Correction to "Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro CYP Induction Studies Including Impact on Drug Interaction Risk Assessment"
4个月前
已完结
Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014
4个月前
已完结
皖公网安备34019202002308
